About this trial
Hyponatremia is the most common electrolyte disorder of all and can be observed in more than 30% of all patients in hospitals. Osmotic homeostasis of body fluids is essential for survival of all living creatures. It is widely accepted that extra- and intracellular osmolalities are in equilibrium at all times and thus, changes in the extracellular osmolality will lead to either shrinkage or swelling of cells which can be detrimental. In severe cases, it can lead to swelling of the brain and death. Even in less dramatic scenarios, symptoms such as epileptic seizures, headaches, depression and dizziness exist, leading to an increased risk of fractures, hospital admissions and a considerable burden for affected patients.
As short-term defense against osmotic stress, each individual cell is capable of actively externalizing or internalizing osmotically active solutes which restores normal or near-normal cell volume at the expense of an altered milieu interior. Obviously, there must be limitations to this strategy if intracellular integrity is meant to be kept stable. It has therefore been postulated that, apart from this cell-immanent mechanism, extracellular and intracellular electrolyte stores could assist in buffering osmotic imbalances.
The Edelman formula states that extracellular sodium is determined by the total amount of exchangeable body sodium (the major extracellular cation) plus potassium (the major intracellular cation) divided by total body water. Several studies have shown, that it only partially explains the changes in patients outside the osmotic equilibrium.
To better understand these physiological responses might not only promote the researcher's insight into the most basic cellular self-defense systems by measuring and comparing extra- and intracellular electrolyte concentrations with estimated changes in a patient that will be intravenously challenged with either water or sodium chloride 3%.
The evolution over time of extra- and intracellular sodium and other electrolytes will be assessed quantitatively in patients with impaired renal function after water or sodium chloride (NaCl) administration.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients ≥18 years
Requirement of renal replacement therapy due to surgical (i.e., nephrectomy) or non-surgical (chronic kidney disease) reason
Stable hemodialysis treatment for at least 3 months
Urine output <100ml in 24 hours
Disqualifiers
Peritoneal dialysis patients
Signs of volume expansion or contraction
Congestive heart failure (NYHA ≥2)
acute illness (infection, congestive heart failure, liver cirrhosis, etc.) requiring hospital admission
Trial design
Parallel
Treatments tested in this trial
Water administration
Other interventionIntravenous administration of water (Aqua ad injectabilia) until a decrease of plasma sodium of 5 to 8 mmol/l has been achieved
NaCl-Administration
Other interventionIntravenous administration of NaCl 3% until an increase of plasma sodium of 5 to 8 mmol/l has been achieved
Treatment groups
Trial outcomes
Primary outcomes
acute changes of extracellular osmolality
The primary aim is to compare the actual acute change of extracellular sodium with the estimated change of extracellular sodium in response to an intravenous challenge with either water or sodium. Precise evaluation of the validity of the concept of Edelman in acute changes of extracellular osmolality
Secondary outcomes
change of extracellular electrolyte concentrations
extracellular electrolyte concentrations in response to an intravenous challenge with either water or sodium.
change of intracellular electrolyte concentrations
intracellular (red blood cells/white blood cells) electrolyte concentrations in response to an intravenous challenge with either water or sodium.
change of osmolality
change of osmolality in response to an intravenous challenge with either water or sodium
change of cell volume
cell volume (red blood cells) in response to an intravenous challenge with either water or sodium
Sponsors and contacts
Click on the lead sponsor to view all of their trials.